 |
 |
NEW YORK (AFX) - Israeli drug developer Taro Pharmaceutical Industries Ltd. said Wednesday it received a U.S. patent for its non-sedating barbiturate compounds aimed at treating essential tremor and Parkinson's disease. The patent expires in June 2025. One compound, called T2000, is in a mid-stage clinical trial in Canada for the treatment of moderate to severe essential tremor. More than six million Americans suffer from both essential tremor and Parkinson's disease, Taro said. Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Production or sales statistics Government regulatory actions ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn